Author

Anthony Paul Conley

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-6232-1163Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Ahsan Saleem FarooqiiD· 1 shared Alexander J. LazariD· 1 shared Anand Kamal SinghiD· 1 shared Angela D. BhallaiD· 1 shared Asha S. MultaniiD· 1 shared Biji ChatterjeeiD· 1 shared Bishal K. Singh· 1 shared Davis R. IngramiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahsan Saleem FarooqiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ATRX Loss Predicts Poor Outcomes and Reveals a Therapeutic Vulnerability to TEAD Inhibition in Soft Tissue Sarcomas

Ryan A. Denu, Anand Kamal Singh, Yingda Jiang, Zhao Zheng, Davis R. Ingram, Khalida Wani, Rossana Lazcano, Madison P. Ginn, Kumaren Anand, Bishal K. Singh, Jackson C. Ballard, Veena Kochat, Biji Chatterjee, William I. Padron, Sharon M. Landers, , Kunal Rai

This study shows ATRX loss in sarcomas correlates with poor outcomes and identifies TEAD inhibition as a potential therapy for ATRX-deficient tumors.

bioRxiv · Nov 23, 2025 · PreprintCancer Biology